HUMAN HERPESVIRUS 2

Investigational

Approval Year

Substance Class	Structurally Diverse Created by `admin` on `Fri Dec 15 20:30:03 GMT 2023` Edited by `admin` on `Fri Dec 15 20:30:03 GMT 2023`
Source Materials Class	ORGANISM
Source Materials Type	VIRUS
Organism Family	Herpesviridae
Organism Genus	Simplexvirus
Organism Species	human herpesvirus 2
Author	NONE
Part	WHOLE
Record UNII	74J6DNH49U
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

HUMAN HERPESVIRUS 2

Common Name

English

HSV-2

Common Name

English

HHV-2

Common Name

English

HERPES SIMPLEX VIRUS-2

Common Name

English

SIMPLEXVIRUS HUMAN HERPESVIRUS 2 WHOLE

Common Name

English

Code System Code Type Description

FDA UNII

74J6DNH49U

Created by admin on Fri Dec 15 20:30:03 GMT 2023 , Edited by admin on Fri Dec 15 20:30:03 GMT 2023

PRIMARY

DAILYMED

74J6DNH49U

Created by admin on Fri Dec 15 20:30:03 GMT 2023 , Edited by admin on Fri Dec 15 20:30:03 GMT 2023

PRIMARY

RXCUI

1318479

Created by admin on Fri Dec 15 20:30:03 GMT 2023 , Edited by admin on Fri Dec 15 20:30:03 GMT 2023

PRIMARY

RxNorm

Related Record Type Details


					H8R8HQ8PME

HERPV COMPONENT HSV-2 GK, GLYCOPROTEIN (304-338)

VACCINE ANTIGEN->TARGET ORGANISM


					LLC792UO2K

HERPV COMPONENT HSV-2 TEGUMENT (9-43)

VACCINE ANTIGEN->TARGET ORGANISM


					WSB956AA7A

HERPV COMPONENT HSV-2 GD, GLYCOPROTEIN (230-264)

VACCINE ANTIGEN->TARGET ORGANISM


					FF6A4962KF

HERPV COMPONENT HSV-2 GH, GLYCOPROTEIN (445-479)

VACCINE ANTIGEN->TARGET ORGANISM


					Z8PX5UX50U

GRIFFITHSIN

INHIBITOR->TARGET ORGANISM


					D148DD5EYX

HERPV COMPONENT HSV-2 DNA PACKING (96-130)

VACCINE ANTIGEN->TARGET ORGANISM


					O06A201GYL

HERPV COMPONENT HSV-2 TEGUMENT (100-134)

VACCINE ANTIGEN->TARGET ORGANISM


					QXF74SSX71

HERPV COMPONENT HSV-2 GK, GLYCOPROTEIN (259-293)

VACCINE ANTIGEN->TARGET ORGANISM


					8L8N9CVS0W

HERPV COMPONENT HSV-2 TEGUMENT (208-242)

VACCINE ANTIGEN->TARGET ORGANISM


					1QV24ETI2J

HERPV COMPONENT HSV-2 TEGUMENT (184-218)

VACCINE ANTIGEN->TARGET ORGANISM


					X4HES1O11F

ACYCLOVIR

INHIBITOR->TARGET ORGANISM

Qualification:

IC50

Amount:


					P202X8XOK3

HERPV COMPONENT HSV-2 ICP27, REGULATION (410-444)

VACCINE ANTIGEN->TARGET ORGANISM


					6CE6P4V5KF

HERPV COMPONENT HSV-2 GJ, ENVELOPE (11-45)

VACCINE ANTIGEN->TARGET ORGANISM


					50X62T0D1H

HERPV COMPONENT HSV-2 GB GLYCOPROTEIN (594-628)

VACCINE ANTIGEN->TARGET ORGANISM


					YF8VM3H7G9

HERPV COMPONENT HSV-2 TEGUMENT (39-73)

VACCINE ANTIGEN->TARGET ORGANISM


					Y3DM9FKY28

HERPV COMPONENT HSV-2 GD, GLYCOPROTEIN (159-193)

VACCINE ANTIGEN->TARGET ORGANISM


					BNR8IX5SIR

HERPV COMPONENT HSV-2 KINASE, TEGUMENT (441-475)

VACCINE ANTIGEN->TARGET ORGANISM


					4G4Z4676IS

BUCICLOVIR

INHIBITOR->TARGET ORGANISM

Comments:

The 9-(3,4-dihydroxybut-1-yl)guanine (bucyclovir, 23) with a hydroxyl directly attached to the butyl side chain is very potent against HSV-1 and HSV-2 (IC50=0.4 μM against HSV-1 and 0.9 μM against HSV-2). The stereochemistry of the 3-position of bucyclovir is crucial in determining the antiherpetic activities. While the R configuration is very potent, the S-isomer (24) is essentially inactive against HSV-1 and HSV-2.

Qualification:

IC50

Amount:


					XB1YMG7SFN

HERPV COMPONENT HSV-2 ICP4, TRANSACTIVATOR (510-544)

VACCINE ANTIGEN->TARGET ORGANISM


					V3DMU7PVXF

RESIQUIMOD

INHIBITOR->TARGET ORGANISM

Amount:


					912WCW4U5J

HERPV COMPONENT HSV-2 GL, ENVELOPE (185-219)

VACCINE ANTIGEN->TARGET ORGANISM


					I0I636QB3J

HERPV COMPONENT HSV-2 TEGUMENT (93-127)

VACCINE ANTIGEN->TARGET ORGANISM


					O99T48RM1P

HERPV COMPONENT HSV-2 GK, GLYCOPROTEIN (159-193)

VACCINE ANTIGEN->TARGET ORGANISM


					GF6VD960F3

HERPV COMPONENT HSV-2 TEGUMENT (77-111)

VACCINE ANTIGEN->TARGET ORGANISM


					QQ29N61F99

HERPV COMPONENT HSV-2 RIBONUCLEOTIDE KINASE (269-303)

VACCINE ANTIGEN->TARGET ORGANISM


					WQQ7Q87NKV

HERPV COMPONENT HSV-2 GB GLYCOPROTEIN (674-708)

VACCINE ANTIGEN->TARGET ORGANISM


					K2W073WG8C

HERPV COMPONENT HSV-2 RNA BINDING, PACKAGING (59-93)

VACCINE ANTIGEN->TARGET ORGANISM


					0Q52900ZX2

HERPV COMPONENT HSV-2 GM, GLYCOPROTEIN (418-452)

VACCINE ANTIGEN->TARGET ORGANISM


					W23P3BC1VC

HERPV COMPONENT HSV-2 TEGUMENT (34-68)

VACCINE ANTIGEN->TARGET ORGANISM


					V3TM3K65V6

HERPV COMPONENT HSV-2 GL, ENVELOPE (90-124)

VACCINE ANTIGEN->TARGET ORGANISM


					3CS1561CUQ

HERPV COMPONENT HSV-2 TEGUMENT (640-674)

VACCINE ANTIGEN->TARGET ORGANISM


					0NYZ8B96AS

HERPV COMPONENT HSV-2 RNA BINDING, PACKAGING (5-39)

VACCINE ANTIGEN->TARGET ORGANISM


					07HQ1TJ4JE

PRITELIVIR

INHIBITOR->TARGET ORGANISM

Amount:


					SZ3TJ0XN1R

HERPV COMPONENT HSV-2 NUCLEAR MEMBRANE (61-95)

VACCINE ANTIGEN->TARGET ORGANISM


					AN1L7O9GIL

HERPV COMPONENT HSV-2 TEGUMENT (26-60)

VACCINE ANTIGEN->TARGET ORGANISM


					W656S9I00W

DENOTIVIR

INHIBITOR->TARGET ORGANISM

Amount:


					DW9N1M1BDH

HERPV COMPONENT HSV-2 TEGUMENT (148-182)

VACCINE ANTIGEN->TARGET ORGANISM


					ZJD4KP074J

HERPV COMPONENT HSV-2 TEGUMENT (145-179)

VACCINE ANTIGEN->TARGET ORGANISM


					359HUE8FJC

PENCICLOVIR

INHIBITOR->TARGET ORGANISM

Comments:

The in vitro activities of penciclovir against HSV-1, HSV-2 and VZV are similar to those of aciclovir, with median IC50 values of 0.4, 1.5 and 4.0 µg/mL, respectively, in MRC-5 cells.

Qualification:

IC50

Amount:

Related Record Type Details


					74J6DNH49U

HUMAN HERPESVIRUS 2

ACTIVE MOIETY